Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Once granted, this patent will:
CHAPEL HILL, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has allowed its patent application with claims covering the use of TNX-103 (oral levosimendan), TNX-102 (subcutaneous levosimendan), TNX-101 (IV levosimendan), the active metabolites of levosimendan (OR1896 and OR18955) and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients and, titled: ”LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF).”
Related news for (TENX)
- Tenax Therapeutics Announces $25 Million Private Placement
- Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
- Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
- Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations
- Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update